I n August 1999, Lexon, Inc. engaged UTEK Corporation to assist Lexon in identifying potential technology acquisitions that would be synergistic with its colon cancer screening technology currently under development. The assay is a blood test for the early detection of colon cancer and certain types of ovarian and testicular cancers.
Lung cancer is the leading cause of cancer deaths worldwide.
The proprietary lung cancer test evolved from research performed at the University of Maryland, Baltimore by a team under the direction of Dr. W. Edward Highsmith. Dr. Highsmith and his group will continue to oversee the Lexon-sponsored development. These tests, when available commercially, are expected to be rapid, accurate, inexpensive, and widely available. Founded in 1992 by M. Keith Ives, the company is a sales and distribution firm which owns the formulas to a line of high quality, all natural preventive health products. All products are made from 98.3 percent pure ingrediants and are guaranteed for potency and purity.